Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology,
CellSpot™, to
find rare human antibodies with superior
selectivity, affinity and other characteristics.
The company has built a pipeline of
four monoclonal antibodies in early stage
development.
